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MATERIALS AND METHODS

Estimating vaccine efficacy
To estimate RR(0 nonparametrically, we use a method based on smoothing scaled residuals from a proportional hazards model (6-9) (details are given in the Appendix). In general, we code vaccine effects with a dichotomous variable z = 1 for vaccine and z = 0 for placebo, with fi{t) as the time-varying coefficient for the vaccine effect. Then our goal is to find the smoothed VE estimate VE(t) = 1-RR(t) = 1 ~ «^°a nd its standard error. The procedure consists of four main steps. The first step is to fit an ordinary proportional hazards model to the data using the partial Nonparametric Estimation of Vaccine Efficacy 949 likelihood function. The second step is to compute the scaled differences between the actual and expected covariate values at each event time. These differences are referred to as Schoenfeld residuals (6, 7) . The third step is to scale these residuals and add the coefficient from the ordinary proportional hazards model. Then, the fourth step is to recover the time-varying regression coefficient, fi(t), by smoothing the sum of the estimated proportional hazards coefficient and the rescaled Schoenfeld residuals over time. Conceptually, we are nonparametrically estimating the instantaneous hazard rate ratio RR(O = e wo . The method also provides a hypothesis test for departures from the proportional hazards assumption (7), the null hypothesis being that the vaccine effect does not vary with time. The null hypothesis of no time-varying effects, or proportional hazards, can be written as HQ : /3(f) = /3 for all t.
Cholera vaccine trial In Bangladesh
As an example, we estimate the efficacy of killed whole-cell-only (WC) and B subunit killed whole-cell (BS-WC) oral cholera vaccines over 4>/2 years of a vaccine trial in rural Matlab, Bangladesh (see Clemens et al. (3) for details). The placebo was a killed Escherichia coli strain. The trial was randomized and double-blinded among 89,596 subjects aged 2-15 years (male and female) and greater than 15 years (females only). We restrict our analyses to subjects that received three doses of vaccine or placebo (i.e., the full vaccination regimen) before May 1, 1985 . There were 20,837, 20,743, and 20,705 such subjects in the placebo, WC, and BS-WC arms of the trial, respectively.
The data have been previously analyzed by Clemens et al. (3) and van Loon et al. (10) using the Poisson rates from successive time periods to assess waning protection.
RESULTS
The events of interest are reported, confirmed cases of cholera illness among the study subjects. Cases were classified into the two major biotypes that circulated during the trial, classic and El Tor cholera. Figure 1 shows a plot of the total number of reported cholera cases for the 4!/2-year period from May 1, 1985 , through November 31, 1989, among subjects that received three doses of vaccine or placebo. Note that cholera incidence was highly seasonal. We computed Kaplan-Meier estimates of the cholera casesurvival curves, S(t), for the placebo and two vaccine groups. Figure 2 shows plots of ln(-lnS(f)) of the Kaplan-Meier estimates of the survival curves for the placebo and two vaccines. The fact that there is good separation between the vaccine and placebo curves indicates that the vaccines give protection. The BS-WC vaccine provides better protection during the first year. The curves slowly approach one another indicating the waning of protective effect, but this is difficult to see with plots based on cumulative incidence.
We used the method described above to estimate smooth plots of the VE(t). The smoothing was carried out with regression splines with four degrees of freedom. In those analyses which were not stratified by age group, we control for age effects by including a term for age group in the model. Figure 3 Figure 4 and tables 2 and 3 give the biotype-specific estimated VE of the two vaccines. There were no classic biotype cholera cases after the third year. On average, both vaccines give better protection against the classic than against the El Tor biotype. The WC vaccine gives fairly constant and significant protection against the classic biotype, with an estimated VE of about 0.65, for the first 2>/2 years of the trial. For the El Tor biotype, such protection is estimated to be about VE = 0.40 for the first 2'/2 years of the trial. The initial VE estimates (i.e., at time zero) for the BS-WC vaccine were 0.848 and 0.715 against the classic and El Tor biotypes, respectively. However, protection waned with time. Figure 5 and tables 4 and 5 give the age-specific estimated VE of the two vaccines. Both vaccines give little protection in the 2-to 5-year age range, but significant protection to those older than age 5 years. Figures 6 and 7, and tables 6-9, give the biotypespecific and age group-specific estimated VE for both vaccines. For the >5 years age range, both vaccines provided significant protection against both biotypes during the first 2 years of the trial. For the 2-to 5-year age range, both vaccines provided some protection against the classic biotype during the first 2 years, but little protection against the El Tor biotype, although the WC vaccine does appear to give some very shortterm protection against the El Tor biotype.
The results of our analyses of the cholera vaccine trial data are similar to the results of the previous analyses of the data (3, 10). In both those analyses, the vaccine trial period was partitioned into discrete periods, usually years. Then, the cholera incidence rates, R, in the placebo and vaccine groups were calculated as the number of cases divided by the number of person-days of risk for each period, i.e., R = (number of cases during the period/person-days of risk during the period). The vaccine efficacy for a period was estimated as l-(/?(vaccinated)//?(placebo)). The usual statistics were computed for period-specific hypothesis tests and confidence intervals. estimate is a bit too low. This discrepancy is largely due to an aberrant large spike of cases in the BS-WC vaccine arm in December 1987, which the nonparametric method presented here smooths out.
Although both vaccines provide protection that wanes with time, figures 3-7 reveal that the waning pattern varies as a function of type of vaccine, infecting cholera subtype, and age group. Overall, the WC vaccine provides fairly constant protection for the first 2 years, followed by a relatively fast decrease in protection. In contrast, the BS-WC vaccine provides better initial protection than the WC vaccine, followed by steady waning over the entire 4 l A years of observation. Although both vaccines protected people in the >5 year age group better than those in the 2-to 5-year age group, figures 6 and 7 reveal considerable interaction. For the 2-to 5-year age group, there appears to be early waning (most pronounced for the El Tor biotype) for the BS-WC vaccine, but not for the WC vaccine. In addition, protection for the first 2 years is nearly identical for the BS-WC and WC vaccine against the classic biotype. In contrast, the WC vaccine gives no protection at all against the El Tor biotype, while the BS-WC vaccine gives only some possible very early protection against the El Tor biotype. For the >5 year age group, the WC vaccine appears to give relatively sustained protection against the classic biotype, and the BS-WC vaccine seems to confer relatively sustained protection against the El Tor biotype. The WC vaccine seems to provide only 2-year protection against the El Tor biotype, and the same seems to be true of the BS-WC vaccine against the classic biotype.
DISCUSSION
We apply a method for nonparametrically estimating VE(f) as a smoothed, continuous function of time since vaccination. Although VE is only estimated at event times, smooth plots of this function help the investigator visualize how the protective effects of the vaccine vary over time. When the VE varies with time since vaccination, there is no simple test for whether the vaccine gives statistically significant protection. There may be significant protection at one time period, but not for another. However, the point-wise 95 percent confidence intervals on the VE(0 provide rough estimates of when the vaccine is providing statistically significant protection. Although we have applied the technique to the problem of detecting and estimating the waning effects of vaccine-induced protection, we could assess any time-dependent vaccine effect (8) . tection may at first increase and then decrease with time.
The results of this method must be interpreted carefully. Smoothed values at the beginning and end of the observation period are uncertain, with large confidence intervals. This is a typical effect of smoothing which is exacerbated when the number of events decreases near the end of die observation period. For example, in the cholera vaccine trial data analyzed in this paper, overall cholera incidence began to drop during the last year of the trial (see figure 1) . Thus, the VE estimates during the last year are unreliable. Nonetheless, the estimated efficacy clearly appears to wane (e.g., see figure 3 ). The approach for estimating VE(f) based on the scaled Schoenfeld residuals (6, 7) provides a graphic interpretation of time-varying effects of VE as well as a test for departure from the proportional hazards assumption. Plots of ln(-lnS(0) are frequently used to assess graphically whether the proportional hazards assumption holds for time-to-event data. Since these are cumulative hazard function plots, they can fail to give a clear picture of time-varying effects that occur later in the study after a substantial number of events have occurred. Figure 2 provides a good illustration of this problem. The placebo and vaccine curves should be roughly parallel for all time if there were no time-varying effects. The early waning of protection of the BS-WC vaccine is readily apparent, especially with respect to the WC vaccine. The placebo and BS-WC are clearly further apart around November 1985 than they are after November 1986. In addition, the protective effects of the two vaccines appear to be converging after November 1986. It is much harder to see the later waning of both vaccines after the first 3 years. Close inspection reveals diat the vaccine and placebo curves are closer together around May 1989 than tfiey are around November 1985. In contrast, the nonparametrically estimated smoothed VE(f) (figure 3) gives a much clearer picture of the time-varying effects. If the proportional hazards assumption were valid, then these curves should be roughly straight lines, with zero slope. We refer to such protection as leaky or as partial protection (11) (12) (13) . The curves in figure 3 clearly have negative slope. In addition, the null hypomesis of a constant effect over time was rejected for both vaccines. This test, however, can be underpowered for small numbers of events (7) .
Different underlying biologic mechanisms, besides waning of protection, can produce time-varying estimates of VE£t). If the immune protection induced by the vaccine is boosted by exposure to natural infection, then the biologic protection at the individual level will increase, and so will the population estimate of VE(7) (14). The methods described here are appropriate to detect increasing protection as well.
Unmeasured heterogeneity of protective effects of the vaccine will also produce time-varying population estimates of VE(f), even when at the individual level the protection induced by the vaccine does not change with time. The most susceptible individuals will tend to become infected first, enriching the population with vaccinated people who have higher protection. The population-level estimate of VE(f) will increase with time even though the individual-level protection is not varying with time. In this case, frailty models can be used to estimate the appropriate efficacy measures of interest (12, 15) . Interpretation of the potential reasons for time-varying estimates of VE(f) is still an open problem and will require use of further information on the underlying biology.
Our analysis provides some insights about the timevarying effects of the vaccines employed in this trial that go beyond those from previous analyses. The cholera toxin B subunit theoretically would provide added short-term protection to a WC vaccine. This hypothesis appears to be confirmed by the early added protection, over the WC vaccine, reflected by the higher early VE{t) for the BS-WC vaccine. Our finding that both vaccines protect better against the classic than the El Tor biotypes could be due to both vaccines containing classic and El Tor cells in a 3-to-l ratio. We also show that both vaccines protected people in the >5 year age group better than those in the 2-to 5-year age group. The reasons for this are unclear. Protection with killed WC cholera vaccine, similar to the one used in Bangladesh, protected those in the 1-to 5-year age group as well as those people >5 years of age in a recent unblinded year-long trial in Vietnam (16) .
The method based on the smoothed, scaled Schoenfeld residuals (6, 7) that we have adapted to construct nonparametric estimates for VE(r) as a smooth continuous function of time provides reliable estimation and analysis of field data. These estimates are virtually assumption-free and provide VE(t) estimation subject to the caveats discussed above. In addition, the method provides a hypothesis test for the presence of timevarying effects (7). Other statistical comparisons can be carried out via the approximate 95 percent confidence intervals. The nonparametrically estimated VE(O curves can also reveal possible parametric forms for VE(O-Once the time-varying nature of the vaccine-induced protection is revealed, researchers may decide to take the second step of parametrically modeling the VE effects. This can increase the efficiency of the VE estimators, increase the power of statistical tests, and lead to a good physical interpretation of vaccine effects. In many cases, the model fitting can be carried out by using the Poisson form of a general linear model (17) or a time-varying Cox model (8, 9) . If there is unmeasured heterogeneity for the vaccine effects, then specially constructed parametric frailty models (12, 15) can be used to estimate VE. Thus, we present a complete framework for estimating VE as a function of time since vaccination. To test whether the vaccine effect is constant over the course of the study, we use the test for a significant linear association between the scaled Schoenfeld residuals and time, as suggested by Grambsch and Therneau (7) . The test has a standard linear models form and incorporates the uncertainty associated with the Cox model estimate. Approximate 95 percent confidence bands for the smooth VE(t) estimates are also computed using ordinary linear models methods. Let sj^k) denote the yth element of 0 + \~l(K /3)r(Jfc, P), and H represent the linear smoother operator matrix. Then the smooth estimate of /3/Q is asymptotically normal with mean 0 and variance Hi^H', where iy is the variance matrix of sj(k). Pointwise standard error bands are constructed using these estimates (18) . To obtain confidence bands on the scale of the VE(t) estimate, we apply the monotonic transformation VE(t) = 1 -exp{/3(f)} to the 95 percent piecewise confidence interval for /?(/) described above.
Analysis and plots were done using modifications of the Splus functions coxph() and cox.zph() (18) . Please contact the authors for further details.
